ABCDx SA, a leader in biomarker-based diagnostics for acute brain disorders, today announced two strategic milestones strengthening its competitive position and licensing opportunities:

• The USPTO has granted ABCDx a patent protecting its novel H-FABP + GFAP diagnostic method for adult traumatic brain injury (TBI).
• The company’s paediatric TBI biomarker study has been published in the Journal of Neurotrauma, confirming the diagnostic value of IL-6–based biomarker panels to safely reduce CT scans and hospital stays in children.

Strategic Value of the Patent

• Exclusive U.S. protection for H-FABP + GFAP biomarker panel.
• Clinically validated in a multicentre study (PLoS ONE, 2018).
• Creates a differentiated, licensable asset in the world’s largest diagnostics market.
• Reinforces ABCDx’s IP portfolio in neurotrauma and stroke.
• Provides non-dilutive revenue opportunities through licensing and partnerships.

Paediatric Publication: Expanding Market Potential

The multicentre paediatric study (419 children, 5 Swiss hospitals) shows that IL-6–based biomarker panels achieve 100% sensitivity and up to 61% specificity, providing a safe and effective triage tool to reduce unnecessary CT scans while ensuring no patient with brain lesions is missed. The work extends ABCDx’s diagnostic platform into the paediatric TBI market, complementing its adult portfolio and broadening commercialization opportunities.

Positioning for Growth

“These two achievements, a U.S. patent grant and a high-impact paediatric publication, reinforce our leadership in brain injury diagnostics,” said Prof. Jean-Charles Sanchez, CEO and Co-founder of ABCDx. “They strengthen our value proposition for investors and partners, as we advance our Series A fundraising and pursue strategic collaborations.”